- BNF:
- 6.1.2.3
- Status:
- Do Not Prescribe (DNP), Grey
- Decision Date:
- July 2016
Comments
GREY:
- Type 2 Diabetes without CKD
- by exceptionality defined as intolerance to the preferred 1st line choice or restricted by its licensing. (Decision date - July 2016).
- NICE TA315: in combination therapy for treating type 2 diabetes. (Decision date - July 2014).
- NICE TA390: as monotherapy for treating type 2 diabetes.
See local type 2 diabetes guidance.
GREY:
- Type 2 diabetes with CKD
- NICE NG28 and NG203 for adults with CKD and type 2 diabetes, in additions to an ACEI or ARB at an optimised dose. (Decision date - Sep 2021, updated Dec 2021, further update Dec 2022).
DNP
- NICE TA1137: (terminated appraisal) Canagliflozin for treating type 2 diabetes in people 10 to 17 years (Decision date March 2026)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
search again
